A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

Exclusion Criteria

• •Skin co-morbidity that would adversely affect the ability to undertake AD assessments
• •Receipt of any vaccine (expect influenza and COVID-19 vaccines) within 3 months prior to screening
• •Receipt of any pneumococcal vaccine within approximate timeframe of 5 years prior to screening
• •Prior receipt of two or more doses of Pneumovax 23 at any time
• •Receipt of any tetanus-, diphtheria-, or pertussis-containing vaccine within approximate timeframe of 5 years prior to screening
• •Participants for whom administration of the pneumococcal vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine
• •Participants for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine
• •Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
• •Known history of or suspected significant current immunosuppression
• •Any malignancies or history of malignancies prior to baseline (excluding non-melanoma skin cancer excised and cured \>5 years prior to baseline)
• •History of solid organ or stem cell transplant
• •Any active or chronic infection including helminthic infection requiring systemic treatment within 2 weeks prior baseline
• •Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit
• •Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
• •The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.